Vaccitech plc (VACC)
Upgrades & Downgrades
Latest VACC news
Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial
Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of sur...
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatiti...
Vaccitech: The Next Big Vaccine Trade
Vaccitech is the company behind the COVID-19 vaccine that was developed in partnership with Oxford University for AstraZeneca. The company has several...
Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the disc...
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the disco...